BridgeBio Oncology Therapeutics Inc (BBOT) Form 4 Filed by Eli M. Wallace, Dec 12, 2025

SEC Form 4 · No Market Transaction

Return To Issuer

Non-market transaction reported.

Reporting Owner

Eli M. Wallace

CEO

TXN 2025-12-10 · FILED 2025-12-12

Filing Lag 2 business days within 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

BridgeBio Oncology Therapeutics Inc

BBOT CIK 0001869105

Reporting Owner

Name	Relationship
Eli M. Wallace CIK 0001776352	Director CEO

Eli M. Wallace at BridgeBio Oncology Therapeutics Inc Full insider history

Bought (12 mo) —

Sold (12 mo) —

More from this insider at BridgeBio Oncology Therapeutics Inc

Derivative Securities Transactions

Title	Strike	Date	Type	Shares	Price	Expiration	Underlying	Ownership
Stock Option (Right to Buy)F2 F1	$12.44	2025-12-10	D - Return to Issuer	1,114,400 D		2035-10-01	1,114,400 Common Stock	Direct

Footnotes (2)

F1: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 2, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Show more
F2: On December 10, 2025, the Issuer rescinded 1,114,400 stock options that were part of the Reporting Person's option grant dated October 2, 2025 (the "Rescinded Portion"). The Rescinded Portion was cancelled and the remaining 500,000 stock options from the original grant continue to remain outstanding. The rescission was an exempt disposition to the Issuer per Rule 16b-3. Show more

5%+ Holders · 13D/G 7 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at BridgeBio Oncology Therapeutics Inc

GET /v1/forms/4/0001193125-25-317962 API docs